618 results on '"Bourlière, M."'
Search Results
2. Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
3. Efficacy, safety and patient‐reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)
4. Chronic hepatitis C: future treatment
5. Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin
6. Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis: a mediation analysis
7. Impact of common risk factors of fibrosis progression in chronic hepatitis C
8. Supplement to: Faldaprevir and deleobuvir for HCV genotype 1 infection.
9. Boceprevir and telaprevir: what have we learned?: O123
10. Facteurs socio-comportementaux associés à la mortalité de cause hépatique et non hépatique chez les patients atteints d’hépatite C chronique (cohorte ANRS CO22 HEPATHER)
11. Co-infection avec les hépatites virales
12. Étude de l'association hépatite auto-immune et antiphospholipides
13. Interim analysis of an interferon (INF)- and ribavirin (RBV)-free regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 in treatment-naive, hepatitis C virus genotype 1-infected patients
14. Les marqueurs sanguins non invasifs de fibrose hépatique au cours de l'infection chronique par le virus de l'hépatite C
15. Hepatitis C therapy in non-genotype 1 patients: the near future
16. Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data
17. Ponction de la surrénale droite sous échoendoscopie : mythe ou réalité ?
18. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial
19. Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV–HCV co-infected patients
20. A national survey of acute hepatitis E in France
21. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection
22. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation
23. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study
24. Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status
25. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study
26. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B
27. Slow viral dynamics of hepatitis C virus genotype 4
28. Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study
29. Lower expression of CD81 B-cell receptor in lymphoproliferative diseases associated with hepatitis C virus infection
30. Serological response to infection with different isolates of hepatitis C virus
31. Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users
32. Résistance aux analogues de nucléosides dans le traitement de l’hépatite chronique B
33. RESISTANCE OF HCV GENOTYPE 4 TO INTERFERON (IFN) ALONE OR TO INTERFERON-RIBAVIRINE
34. EFFICACY AND TOLERABILITY OF HBV VACCINE IN CHRONIC HEPATITIS C PATIENTS (CHC)
35. Dépistage prospectif de la fibrose hépatique à l’aide du Fib-4 calculé automatiquement lors d’un bilan biologique chez 29 707 sujets français
36. Sustained virological response to Do hepatitis C DAA treatments in migrants and non-migrants groups
37. HBV and HIV screening, and hepatitis B immunization programme in the prison of Marseille, France
38. C01/156 IIMPACT OF HGV / GBV-C INFECTION ON PATIENTS WITH CHRONIC HEPATITS C
39. Comment conduire des actes de recherche clinique en milieu libéral: de nombreuses difficultés?
40. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus‐infected patients with renal impairment: results from a 7‐year, multicentre retrospective cohort study.
41. Prevalence of HCV and HIV antibodies and related risk factors among entrants to the main southeastern French prison
42. Indeterminate Second-Generation Hepatitis C Recombinant Immunoblot Test: Detection of Hepatitis C Virus Infection by Polymerase Chain Reaction
43. Hepatitis C Virus Genotypes in Chronic Hepatitis and Response to Interferon-α Therapy
44. Utilisation pratique de l’écho-endoscopic (EUS) pour le suivi quotidien des patients cirrhotiques
45. Efficacy, safety and patient‐reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)
46. Carcinome hépatocellulaire et traitements antiviraux contre le VHB et le VHC
47. SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 Weeks in DAA-naïve patients: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 and POLARIS-4 studies
48. Treatment with SOF/VEL or SOF/VEL/VOX is well tolerated and results in high SVR12 in genotype 1–6 HCV infected patients with minimal fibrosis: a retrospective analysis of the ASTRAL and POLARIS clinical studies
49. Treatment and prognosis of acute severe autoimmune hepatitis
50. No impact of RASs on the high efficacy of SOF/VEL/VOX for 12 weeks in DAA-experienced patients: an integrated resistance analysis of the POLARIS-1 and POLARIS-4 studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.